Skip to main content
. 2021 Apr 20;59(5):e02890-20. doi: 10.1128/JCM.02890-20

FIG 2.

FIG 2

Detection rates by a commercial microarray (Viramed) in 354 blood samples longitudinally obtained from 81 hospitalized IgG-seroconverting patients with acute SARS-CoV-2 infection, grouped by a 2-day interval (one sample per patient per interval step). (A) S1-, S2-, and NCP-specific IgM antibodies; (B) S1-, S2-, and NCP-specific IgA antibodies; (C) S1-, S2-, and NCP-specific IgG antibodies.